Mochida Pharmaceutical Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Naoyuki Mochida

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	25.3yrs
Participación del CEO	3.2%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	6.8yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Naoyuki Mochida

25.3yrs

Permanencia

Mr. Naoyuki Mochida is President of Mochida Pharmaceutical Co., Ltd. from January 1999 and serves as its Representative Director since January 1999. Mr. Mochida joined the Mochida Pharmaceutical Co., Ltd....

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Naoyuki Mochida	President & Representative Director	25.3yrs	sin datos	3.22% ¥ 21.4m
Masayoshi Takeda	GM, Head of Finance & Accounting Department and Full-Time Audit & Supervisory Board Member	1.8yrs	sin datos	0.0014% ¥ 9.4k
Keiichi Sagisaka	Senior Executive Managing Officer of Pharmaceutical Business & Healthcare and Director	13.8yrs	sin datos	sin datos
Chu Sakata	Senior EVP & Representative Director	12.8yrs	sin datos	0.037% ¥ 243.9k
Kiyoshi Mizuguchi	Exec Managing Officer of Research & Development	8.8yrs	sin datos	0.016% ¥ 105.0k
Junichi Sakaki	Senior Exec Managing Officer of Business Development	9.8yrs	sin datos	0.025% ¥ 165.1k
Yutaka Kawakami	Executive Managing Officer	4.8yrs	sin datos	0.013% ¥ 88.2k
Motoi Mitsuishi	Member of the Board & Executive Managing Officer	1.3yrs	sin datos	sin datos
Tomoo Kugisawa	Independent Outside Director	11.8yrs	sin datos	0.0096% ¥ 63.8k
Nana Otsuki	Independent Outside Director	2.8yrs	sin datos	0.0014% ¥ 9.4k
Tomoaki Sonoda	Independent Outside Director	1.8yrs	sin datos	0.00056% ¥ 3.7k
Shigeaki Yoshikawa	Independent Outside Director	1.3yrs	sin datos	sin datos

6.8yrs

Permanencia media

Junta con experiencia: La junta directiva de MFY se considera experimentada (6.7 años de antigüedad promedio).

Mochida Pharmaceutical Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023

Less than half of directors are independent

Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2022

Less than half of directors are independent

Recent updates

Upcoming dividend of JP¥40.00 per share

Mochida Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 13, 2024

Third quarter 2024 earnings released: EPS: JP¥45.16 (vs JP¥112 in 3Q 2023)

Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Mochida Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 05, 2024

Second quarter 2024 earnings released: EPS: JP¥32.02 (vs JP¥20.52 in 2Q 2023)

Upcoming dividend of JP¥40.00 per share at 2.4% yield

Mochida Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 02, 2023

First quarter 2024 earnings released: EPS: JP¥46.23 (vs JP¥83.98 in 1Q 2023)

Mochida Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 04, 2023

Full year 2023 earnings released: EPS: JP¥179 (vs JP¥277 in FY 2022)

Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023

Upcoming dividend of JP¥40.00 per share at 2.4% yield

Third quarter 2023 earnings released: EPS: JP¥112 (vs JP¥138 in 3Q 2022)

Mochida Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 06, 2023

Second quarter 2023 earnings released: EPS: JP¥20.52 (vs JP¥59.14 in 2Q 2022)

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: JP¥20.52 (vs JP¥59.14 in 2Q 2022)

Upcoming dividend of JP¥40.00 per share

Mochida Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 04, 2022

First quarter 2023 earnings released: EPS: JP¥83.98 (vs JP¥69.33 in 1Q 2022)

Mochida Pharmaceutical Co., Ltd. (TSE:4534) announces an Equity Buyback for 1,190,000 shares, representing 3.17% for ¥3,500 million.

Mochida Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022

Full year 2022 earnings released: EPS: JP¥277 (vs JP¥222 in FY 2021)

Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2022

Less than half of directors are independent

Mochida Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022

Upcoming dividend of JP¥40.00 per share

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Second quarter 2022 earnings released: EPS JP¥59.13 (vs JP¥52.74 in 2Q 2021)

Upcoming dividend of JP¥40.00 per share

First quarter 2022 earnings released: EPS JP¥69.33 (vs JP¥86.88 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥222 (vs JP¥118 in FY 2020)

Upcoming dividend of JP¥40.00 per share

New 90-day high: €33.80

Third quarter 2021 earnings released: EPS JP¥77.56 (vs JP¥45.66 in 3Q 2020)

Revenue beats expectations

Mochida Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Feb 05, 2021

New 90-day low: €29.80

Revenue misses expectations

Second quarter 2021 earnings released: EPS JP¥52.74

Revenue misses expectations

Second quarter 2021 earnings released: EPS JP¥52.74

New 90-day high: €34.80

New 90-day low - €29.60

First quarter earnings released

CEO

Permanencia

Miembros de la Junta

Permanencia media